Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Jørgen G Bramness, Øystein Hoel Gundersen, Joar Guterstam and 6 more

BMC Psychiatry · 2012 · Review

doi:10.1186/1471-244x-12-221

Abstract

Use of amphetamine and methamphetamine is widespread in the general population and common among patients with psychiatric disorders. Amphetamines may induce symptoms of psychosis very similar to those of acute schizophrenia spectrum psychosis. This has been an argument for using amphetamine-induced psychosis as a model for primary psychotic disorders. To distinguish the two types of psychosis on the basis of acute symptoms is difficult. However, acute psychosis induced by amphetamines seems to have a faster recovery and appears to resolve more completely compared to schizophrenic psychosis. The increased vulnerability for acute amphetamine induced psychosis seen among those with schizophrenia, schizotypal personality and, to a certain degree other psychiatric disorders, is also shared by non-psychiatric individuals who previously have experienced amphetamine-induced psychosis. Schizophrenia spectrum disorder and amphetamine-induced psychosis are further linked together by the finding of several susceptibility genes common to both conditions. These genes probably lower the threshold for becoming psychotic and increase the risk for a poorer clinical course of the disease.The complex relationship between amphetamine use and psychosis has received much attention but is still not adequately explored. Our paper reviews the literature in this field and proposes a stress-vulnerability model for understanding the relationship between amphetamine use and psychosis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Background

Amphetamine and methamphetamine (hereafter amphetamines) can prolong wakefulness, increase focus and feelings of energy as well as decrease fatigue. They can produce euphoria, induce anorexia, and be used to treat narcolepsy and attention deficit/hyperactivity disorder (ADHD). Adverse effects include anxiety, aggression, paranoia, hyperactivity, reduced appetite, tachycardia, increased breathing rate, dilated pupils, increased blood pressure, headache, insomnia, palpitations, arrhythmia and others.

Amphetamines inhibit dopamine reuptake by interacting with the dopamine transporter (DAT), thereby increasing the concentration of dopamine in the synaptic cleft. Amphetamines also interact with the vesicular monoamine transporter 2 (VMAT2), leading to increasing amounts of dopamine in the cytosol, a possible mechanism of action for the neurotoxicity of amphetamines. Neurotoxic effects are seen also in serotonergic and noradrenergic neurons.

Amphetamines are highly addictive drugs. Both amphetamine and methamphetamine act directly on the mesolimbic dopaminergic “reward system” by inducing release of dopamine, and to some extent norepinephrine, in the synaptic clefts of the Nucleus Accumbens (NAc) and other terminal areas provoking a euphoric state, but also addiction.

Abuse of amphetamines is widespread in the general population. It is also common among psychiatric patients, where a high percentage test positive for amphetamines.

There is overwhelming evidence that patients with psychotic disorders have an increased vulnerability to compulsive use of drugs of abuse, including psycho stimulants like amphetamines. This may be especially true for patients with schizophrenia like disorders. There may be several explanations for this increased co morbidity, but there is convincing evidence from animal studies that this may be due to shared vulnerabilities for both psychosis and drug use disorders. These animal studies also point to possible neural mechanisms explaning the increased co morbidity.

The association between amphetamine use and psychosis has received much attention, but several questions about this complex relationship remain unanswered. In the following, we review some of these questions and propose a new model for understanding the relationship between amphetamine use and psychosis.

Prevalence and clinical presentation

Observations strongly suggest a relationship between the intake of amphetamines and the development of acute psychosis. First, early studies demonstrated that amphetamines could trigger acute psychosis in healthy subjects. In these studies, amphetamine was given in consecutively higher doses until psychosis was precipitated, often after 100–300 mg of amphetamine. The symptoms subsided within 6 days. The effect was blocked by the use of anti-psychotics. Not all the subjects in these studies became psychotic, as some had to be removed from the experiment because of health risks caused by elevation of heart rate, blood pressure or body temperature. Secondly, psychosis has been viewed as an adverse event, although rare, in children with ADHD who have been treated with amphetamine. Thirdly, drug-induced psychosis has been reported in 8–46% of regular users of amphetamines. The wide variation is probably due to different populations being studied, gender and the method and duration of amphetamine use. It may also depend on the instruments used to assess psychosis, e.g. self-report vs. formal diagnostic instruments. Lastly, there is a positive correlation between amphetamine availability at a community level and the incidence of psychosis in the same population.

Amphetamine has a terminal elimination half life (T½) of 12–15 hours and is often taken several times over the course of many days in runs or binges. There is clinical evidence that such binges may end in psychosis. Surprisingly, it is poorly understood, whether such psychosis is due to amphetamine use per se (amount over time, amount on one occasion or the length of the current binge), vulnerabilities in the user or both. It could be that psychosis occurs because of the sleep deprivation that follows amphetamine use, or because of other factors at the end of a binge. Users will often end their binge by using sedating drugs like alcohol, benzodiazepines, opiates or cannabis. This could be viewed as self-medication and may be one reason why users often develop problems with several drugs. Only a weak relationship has been reported between psychotic symptoms and the level of amphetamines in the blood of psychotic patients. This could be because acute blood levels at the end of a binge are a poor representation of overall amphetamine exposure, but it could also be because individual vulnerability, rather than level of amphetamine exposure, is the critical risk factor for developing acute psychosis.

The symptoms of psychosis induced by amphetamines are very similar to those of acute schizophrenia spectrum psychosis and include: lack of concentration, delusions of persecution, increased motor activity, disorganization of thoughts, lack of insight, anxiety, suspicion and auditory hallucinations. Some studies have suggested differences with more pronounced grandiosity and visual hallucinations. The thought disorders that occur in schizophrenia characterized by a splitting and loosening of associations, a concreteness of abstract thought, and an impairment in goal-directed thought, may be less prominent in amphetamine induced psychosis. However, distinguishing the two types of psychosis on the basis of acute symptoms is probably very difficult. The similarities between the two conditions are, in fact, so pronounced that this has been used as an argument for using amphetamine-induced psychosis as a model for primary psychotic disorders.

In contrast to schizophrenic psychosis, acute psychosis induced by amphetamines seems to have a faster recovery, and appears to resolve with abstinence, although the recovery may be incomplete. Japanese researchers have argued that psychosis induced by amphetamines could, in fact, be of much longer duration, up to several years. This research describes spontaneous psychotic relapses in the long term after remittance of psychosis (“flashbacks”), a phenomenon acknowledged in the popular folk culture in the USA and Europe, but much less researched. Stressful situations seem to trigger such flashbacks in susceptible individuals and several vulnerability factors have been identified, e.g. a family history of psychosis. It is difficult to distinguish the Japanese chronic amphetamine psychosis from a primary psychosis triggered by the use of amphetamines, although it has been claimed that they constitute separate entities.

Risk factors and acute vs. chronic psychosis

In animal models, there is sensitization to the rewarding effects of amphetamines (e.g.). Sensitization is also seen in human subjects. There is reason to believe that an earlier psychosis involves a risk of future psychotic episodes due to this sensitization, or possibly to the development of dopaminergic super sensitivity. Psychosis may be precipitated acutely by amphetamine due to its effects on dopaminergic activity in the CNS. In the longer term, the neurotoxic effects of the drugs on serotonin and dopamine neurons and dopamine transporters may play a role. Amphetamine sensitization seems to cause dysregulation of dopamine by the ventral subiculum. There is an over-expression of the dopamine receptor, subtype 2 (DRD2) and a higher sensitivity of DRD2 to the effects of amphetamines in vulnerable individuals.

In addition to the increased risk of psychosis following the use of amphetamines in people who have experienced amphetamine-induced psychosis previously, patients with schizophrenia and schizotypal personality traits may more readily become psychotic after the use of amphetamines. Other risk factors for psychosis may include amphetamine use disorders (abuse and dependence), the presence of other psychiatric disorders (primarily attenuated psychosis syndrome, personality disorders and affective disorders), early cognitive dysfunction (such as those found in the prodromal states of schizophrenia), family history of mental disorder and the use of other drugs like opiates, benzodiazepines, cannabis and alcohol.

Several susceptibility genes have been found in common for amphetamine-induced psychosis and schizophrenia. These genes increase the risk both for becoming psychotic and for a poorer clinical course of the disease. Studies in Japan also indicate that primary and drug induced psychosis may be genetically linked. Relatives of methamphetamine-users with a lifetime history of amphetamine psychosis are 5 times more likely to have schizophrenia than methamphetamine-users without a history of psychosis. Patients with schizophrenia and those with psychosis induced by amphetamines both show significantly increased peripheral plasma levels of norepinephrine compared to methamphetamine users who do not have psychosis, and to non-using conrols. This seemingly common vulnerability is important considering the difficulties in distinguishing between the two conditions in the long term.

The precipitation of psychosis by amphetamines in healthy subjects can be blocked by anti-psychotics. Similarly, psychotic symptoms caused by amphetamines can, like acute schizophrenic psychosis, be treated with anti-psychotics. A Cochrane review from 2009 identified only one randomized controlled trial of treatment for psychosis induced by amphetamines which met the criteria for included studies. It showed that both olanzapine and haloperidol in clinically relevant doses were effective in treating psychotic symptoms. One problem with using anti-psychotics could be that such drugs have a tendency to block the DRD2, potentially increasing anhedonia that could, in turn, cause a greater vulnerability to relapse into drug abuse. Some studies indeed point in this direction. The use of alternative therapeutic drugs, such as benzodiazepines, will reduce the chance of extra pyramidal adverse effects and decrease the risk of intoxication. However, one argument against this strategy is that anti-psychotics seem to protect against the neurotoxic effects of amphetamines.

To further complicate the situation, it seems that up to 25% of those initially diagnosed with drug induced psychosis after some years develope a primary psychotic disorder, and even higher figures when looking at methamphetamine induced psychosis. This leaves us with a dilemma - how valid is a diagnostic construct of amphetamine induced psychosis? Such a term suggests the assumption that this type of psychosis can be induced in individuals otherwise not susceptible to, e.g. schizophrenia or other primary psychotic disorders. The ambiguity and difficulties of this diagnosis are reflected in a recent review where the authors suggest the alternative term “substance-associated psychosis” and state that there is a dearth of research that rigorously examines the validity of the diagnostic criteria across substances. These researchers identified 18 papers that specifically focused on delineating the clinical characteristics or outcomes of individuals diagnosed with substance-induced psychosis. Seven of these papers focused on stimulants (amphetamines and cocaine), but only one had a 1 year follow-up assessment.

Also for other substances of abuse with a tendency to cause psychosis there have been similar discussions. It has long been recognized that the use of cannabis in early adolescence increases the risk of later development of psychosis and schizophrenia. Because the drug intake takes place many years before the diagnosis of schizophrenia it has been argued that this cannot be a case of reversed causality. There are however some arguments in the opposite direction. Firstly, even with a formidable increase in the use of cannabis in the population, no increase in the incidence of schizophrenia has been observed. Secondly, it has been shown that patients with schizophrenia may have their psychosis triggered by lower intake of cannabis than healthy volunteers. Lastly, we do not know when a psychotic disorder starts to develop. It may be that it starts long before the initial psychotic symptoms, opening for the possibility of reversed causality, even when intake of cannabis takes place years before first psychotic episode. The present agreement in the field seems to be that cannabis can precipitate psychosis in vulnerable individuals, an agreement that closely resembles our suggested model. The similarities between amphetamines’ and cannabis’ risk of being associated with later psychosis is further supported by a newly published record linkage study.

A model for the relationship between psychosis induced by amphetamines and primary psychotic disorder

The similarities between acute schizophrenic psychosis and psychosis following the use of amphetamines are so pronounced that the latter has been suggested as a model for schizophrenia. However, it remains unresolved whether the relationship between amphetamines and psychosis is explained by drug exposure (amphetamine-induced psychosis), amphetamines use triggering a primary psychotic disorder or both. Although psychosis may be induced by amphetamine in healthy individuals, not all subjects become psychotic by the doses of amphetamines allowed in the experiments. Some, but not all, individuals using amphetamines have experienced psychotic episodes, and a few have experienced psychosis as an adverse event during stimulant treatment. Is this a result of differences in amphetamine exposure or differences in vulnerability? Furthermore, psychosis is precipitated by a lower dose of amphetamines in individuals with primary psychosis and may be blocked by the use of anti-psychotics. Finally, there seem to be many genetic and physiological similarities between amphetamine-induced psychosis and acute schizophrenic psychosis, suggesting that vulnerability may play a significant role in the occurrence of amphetamines-induced psychosis.

In this context, we hypothesize that the relationship between amphetamine-induced psychosis and primary psychosis can be viewed within the framework of a traditional vulnerability stress paradigm (Figure 1). Exposure to amphetamines should be viewed as a stressor in the acute phase for the vulnerable individual in a dynamic way; for individuals with lower vulnerability higher doses of amphetamines are needed, whereas individuals with higher vulnerability require lower doses to precipitate acute psychosis. In addition, due to their sensitizing effects, amphetamines may also play a role in the development of vulnerability. Repeated use of amphetamines could increase vulnerability, thereby increasing the chances of developing psychotic symptoms even in the absence of (acute exposure to) amphetamines. Thus, primary psychotic disorder and psychosis precipitated by amphetamines need not be considered as two separate phenomena, but as two phenomena interlinked in a dynamic way.

Taking such a view may have some important clinical implications. Patients diagnosed with drug induced psychosis following intake of amphetamines should be monitored more closely, in particular for signs of a chronic development. Any further use of amphetamines should be strongly discouraged, since it would constitute an acute stressor that could precipitate psychosis and increase the individual’s vulnerability to developing a more chronic psychotic disorder. This model also provides a rationale for future studies of preventive anti-psychotic treatment, including psycho-social, psycho-educational and possibly also pharmacological interventions to decrease vulnerability, in the same way as is recommended for individuals with a primary psychotic disorder.

Competing interests

None of the authors have any conflicts of interest to declare.

Authors’ contributions

All the authors have contributed substantially to the idea, structure and content of the paper. All authors have discussed all concepts and formulations in the final manuscript and have approved the submitted versions. JGB has, as first author, written the first draft of all the sections, but these have been altered and reformulated by all the authors in several collaborating rounds.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-244X/12/221/prepub

References 108

  1. 1.

    Lineberry TW Bostwick JM Methamphetamine abuse: a perfect storm of complicationsMayo Clin Proc2006 8117784

    Not in our library10.4065/81.1.77

  2. 2.

    Seiden LS Sabol KE Ricaurte GA Amphetamine: effects on catecholamine systems and behaviorAnnu Rev Pharmacol Toxicol1993 33639677

    Not in our library10.1146/annurev.pa.33.040193.003231

  3. 3.

    Robinson TE Berridge KC The psychology and neurobiology of addiction: an incentive-sensitization viewAddiction2000 95Suppl 2S91S117

    Not in our library10.1080/09652140050111681

  4. 4.

    Degenhardt L Roxburgh A McKetin R Hospital separations for cannabis- and methamphetamine-related psychotic episodes in AustraliaMed J Aust2007 1867342345

    Not in our library10.5694/j.1326-5377.2007.tb00933.x

  5. 5.

    Degenhardt L Roxburgh A Black E Bruno R Campbell G Kinner S The epidemiology of methamphetamine use and harm in AustraliaDrug Alcohol Rev2008 273243252

    Not in our library10.1080/09595230801950572

  6. 6.
    Prevalence of nonmedical methamphetamine use in the United States · 2008
    Not checked
  7. 7.

    Maxwell JC Rutkowski BA The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992–2007Drug Alcohol Rev2008 273229235

    Not in our library10.1080/09595230801919460

  8. 8.

    McKetin R Kozel N Douglas J Ali R Vicknasingam B Lund J The rise of methamphetamine in Southeast and East AsiaDrug Alcohol Rev2008 273220228

    Not in our library10.1080/09595230801923710

  9. 9.

    Odegård Lund M Skretting A Lund K Rusmiddelbruk blant unge voksne, 21–30 år2007 Oslo: Statens Institutt for Rusmiddelforskning

    Not in our library

  10. 10.

    Gonzales R Ang A McCann MJ Rawson RA An emerging problem: methamphetamine abuse among treatment seeking youthSubst Abus2008 2927180

    Not in our library10.1080/08897070802093312

  11. 11.

    Katz G Durst R Shufman E Bar-Hamburger R Grunhaus L Substance abuse in hospitalized psychiatric patientsIsr Med Assoc J2008 1010672675

    Not in our library

  12. 12.

    Mordal J Bramness JG Holm B Morland J Drugs of abuse among acute psychiatric and medical admissions: laboratory based identification of prevalence and drug influenceGen Hosp Psychiatry2008 3015560

    Not in our library10.1016/j.genhosppsych.2007.10.006

  13. 13.

    Cantor-Graae E Nordstrøm LG McNeil TF Substance abuse in schizophrenia: a review of the literature and a study of correlates in SwedenSchizophr Res2001 4816982

    Not in our library10.1016/s0920-9964(00)00114-6

  14. 14.

    Regier DA Farmer ME Rae DS Locke BZ Keith SJ Judd LL Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) StudyJAMA1990 2641925112518

    Not in our library10.1001/jama.1990.03450190043026

  15. 15.

    Ringen PA Melle I Birkenaes AB Engh JA Faerden A Vaskinn A The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illnessActa Psychiatr Scand2008 1184297304

    Not in our library10.1111/j.1600-0447.2008.01244.x

  16. 16.

    Ringen PA Lagerberg TV Birkenaes AB Engn J Faerden A Jonsdottir H Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorderPsychol Med2008 38912411249

    Not in our library10.1017/s003329170700236x

  17. 17.

    Chambers RA Krystal JH Self DW A neurobiological basis for substance abuse comorbidity in schizophreniaBiol Psychiatry2001 5027183

    Not in our library10.1016/s0006-3223(01)01134-9

  18. 18.

    Chambers RA Sentir AM Engleman EA Ventral and dorsal striatal dopamine efflux and behavior in rats with simple vs. co-morbid histories of cocaine sensitization and neonatal ventral hippocampal lesionsPsychopharmacology (Berl)2010 21217383

    Not in our library10.1007/s00213-010-1929-1

  19. 19.

    Paparelli A Di FM Morrison PD Murray RM Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of lightFront Behav Neurosci2011 51

    Not in our library10.3389/fnbeh.2011.00001

  20. 20.

    Angrist BM Gershon S The phenomenology of experimentally induced amphetamine psychosis–preliminary observationsBiol Psychiatry1970 2295107

    Not in our library

  21. 21.

    Bell DS The experimental reproduction of amphetamine psychosisArch Gen Psychiatry1973 2913540

    Not in our library10.1001/archpsyc.1973.04200010020003

  22. 22.

    Griffith JJ Oates J Cavanaugh J Paranoid episodes induced by drugsJAMA1968 20536

    Not in our library

  23. 23.

    Janowsky DS Risch C Amphetamine psychosis and psychotic symptomsPsychopharmacology (Berl)1979 6517377

    Not in our library10.1007/bf00491982

  24. 24.

    Espelin DE Done AK Chlorpromazine vs. amphetamineN Engl J Med1968 2796329

    Not in our library

  25. 25.

    Calello DP Osterhoudt KC Acute psychosis associated with therapeutic use of dextroamphetaminePediatrics2004 11351466

    Not in our library10.1542/peds.113.5.1466

  26. 26.

    Lucas AR Weiss M Methylphenidate hallucinosisJAMA1971 217810791081

    Not in our library10.1001/jama.1971.03190080041008

  27. 27.

    Ross RG Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorderAm J Psychiatry2006 163711491152

    Not in our library10.1176/appi.ajp.163.7.1149

  28. 28.

    Spear J Alderton D Psychosis associated with prescribed dexamphetamine useAust N Z J Psychiatry2003 373383

    Not in our library10.1046/j.1440-1614.2003.11723.x

  29. 29.

    Surles LK May HJ Garry JP Adderall-induced psychosis in an adolescentJ Am Board Fam Pract2002 156498500

    Not in our library

  30. 30.

    Young D Serorille WB Paranoid psychosis in narcolepsy and possible dangers of benzedrine treatmentMed Clin North Am1938 22637643

    Not in our library

  31. 31.

    Glasner-Edwards S Mooney LJ Marinelli-Casey P Hillhouse M Ang A Rawson R Clinical course and outcomes of methamphetamine-dependent adults with psychosisJ Subst Abuse Treat2008 354445450

    Not in our library10.1016/j.jsat.2007.12.004

  32. 32.

    Grant KM Levan TD Wells SM Li M Stoltenberg SF Gendelman HE Methamphetamine-Associated PsychosisJ Neuroimmune Pharmacol2011 71113139

    Not in our library10.1007/s11481-011-9288-1

  33. 33.

    Leamon MH Flower K Salo RE Nordahl TE Kranzler HR Galloway GP Methamphetamine and paranoia: the methamphetamine experience questionnaireAm J Addict2010 192155168

    Not in our library10.1111/j.1521-0391.2009.00014.x

  34. 34.

    McKetin R McLaren J Lubman DI Hides L The prevalence of psychotic symptoms among methamphetamine usersAddiction2006 1011014731478

    Not in our library10.1111/j.1360-0443.2006.01496.x

  35. 35.

    Shoptaw S Peck J Reback CJ Rotheram-Fuller E Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatmentJ Psychoactive Drugs2003 35Suppl 1161168

    Not in our library10.1080/02791072.2003.10400511

  36. 36.

    Wallace C Galloway T McKetin R Kelly E Leary J Methamphetamine use, dependence and treatment access in rural and regional North Coast of New South Wales, AustraliaDrug Alcohol Rev2009 286592599

    Not in our library10.1111/j.1465-3362.2008.00016.x

  37. 37.

    Yen CF Chong MY Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: a case–control studyCompr Psychiatry2006 473215220

    Not in our library10.1016/j.comppsych.2005.07.006

  38. 38.

    Mahoney JJ Hawkins RY De La Garza R Kalechstein AD Newton TF Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participantsGend Med2010 75414421

    Not in our library10.1016/j.genm.2010.09.003

  39. 39.

    Matsumoto T Kamijo A Miyakawa T Endo K Yabana T Kishimoto H Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administrationAddiction2002 977809817

    Not in our library10.1046/j.1360-0443.2002.00143.x

  40. 40.

    Grant KM Kelley SS Agrawal S Meza JL Meyer JR Romberger DJ Methamphetamine use in rural MidwesternersAm J Addict2007 1627984

    Not in our library10.1080/10550490601184159

  41. 41.

    Medhus S Mordal J Holm B Mørland J Bramness JG A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wardsPsychiatry research2012

    Not in our library10.1016/j.psychres.2012.09.023

  42. 42.

    Sara G Burgess P Malhi G Whiteford H Amphetamine availability and admissions for psychosis in New South Wales, 2001–2009Aust N Z J Psychiatry2011 454317324

    Not in our library10.3109/00048674.2010.547455

  43. 43.

    Ujike H Sato M Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosisAnn N Y Acad Sci2004 1025279287

    Not in our library10.1196/annals.1316.035

  44. 44.

    Vos PJ Cloete KJ Le RA Kidd M Jordaan GP A retrospective review of trends and clinical characteristics of methamphetamine-related acute psychiatric admissions in a South African contextAfr J Psychiatry (Johannesbg )2010 135390394

    Not in our library10.4314/ajpsy.v13i5.63105

  45. 45.

    de la Torre R Farre M Navarro M Pacifici R Zuccaro P Pichini S Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matricesClin Pharmacokinet2004 433157185

    Not in our library10.2165/00003088-200443030-00002

  46. 46.

    Segal DS Kuczenski R An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristicsJ Neurosci1997 17725512566

    Not in our library10.1523/jneurosci.17-07-02551.1997

  47. 47.

    Semple SJ Zians J Grant I Patterson TL Impulsivity and methamphetamine useJ Subst Abuse Treat2005 2928593

    Not in our library10.1016/j.jsat.2005.05.001

  48. 48.

    Semple SJ Zians J Strathdee SA Patterson TL Psychosocial and behavioral correlates of depressed mood among female methamphetamine usersJ Psychoactive Drugs2007 4Suppl353366

    Not in our library10.1080/02791072.2007.10399897

  49. 49.

    Williamson S Gossop M Powis B Griffiths P Fountain J Strang J Adverse effects of stimulant drugs in a community sample of drug usersDrug Alcohol Depend1997 442–38794

    Not in our library10.1016/s0376-8716(96)01324-5

  50. 50.

    Volkow Nora D NIDA Research ReportMethamphetamine Abuse and Addiction2006 Washington: National Institute on Drug Abuse

    Not in our library

  51. 51.

    Medhus S Mordal J Holm B Mørland J Bramness JG Symptoms and drug use among (meth)amphetamine positive patients admitted to the acute psychiatric wardPsychiatr Res2012 in press

    Not in our library

  52. 52.

    Harris D Batki SL Stimulant psychosis: symptom profile and acute clinical courseAm J Addict2000 912837

    Not in our library10.1080/10550490050172209

  53. 53.

    Jonsson LE Sjostrom K A rating scale for evaluation of the clinical course and symptomatology in amphetamine psychosisBr J Psychiatry1970 117541661665

    Not in our library10.1192/bjp.117.541.661

  54. 54.

    Srisurapanont M Ali R Marsden J Sunga A Wada K Monteiro M Psychotic symptoms in methamphetamine psychotic in-patientsInt J Neuropsychopharmacol2003 64347352

    Not in our library10.1017/s1461145703003675

  55. 55.

    Yui K Ikemoto S Ishiguro T Goto K Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophreniaAnn N Y Acad Sci2000 914112

    Not in our library10.1111/j.1749-6632.2000.tb05178.x

  56. 56.

    Srisurapanont M Arunpongpaisal S Wada K Marsden J Ali R Kongsakon R Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysisProg Neuropsychopharmacol Biol Psychiatry2011 354959964

    Not in our library10.1016/j.pnpbp.2011.01.014

  57. 57.

    Bell DS Comparison of amphetamine psychosis and schizophreniaBr J Psychiatry1965 111701707

    Not in our library10.1192/bjp.111.477.701

  58. 58.

    Bousman CA Glatt SJ Everall IP Tsuang MT Ritsner MSMethamphetamine-Associated Psychosis: A model for Biomarker Discovery in SchizofreniaHandbook of Schizophrenia Spectrum Disorders Volume 12011 Dordrecht: Springer Science+Business Media B.V327343

    Not in our library

  59. 59.

    Ellinwood EH Amphetamine Psychosis: I. Description of the Individuals and ProcessJ Nerv Ment Dis1967 1444273283

    Not in our library10.1097/00005053-196704000-00005

  60. 60.

    Connell PH Amphetamine Psychosis. Maudsley Monograph No. 51958 London: Oxford University Press

    Not in our library

  61. 61.

    McIver C McGregor C Baigent M Spain D Newcombe D Ali R Guidelines for the medical management of patients with methamphetamine-induced psychosis2006 South Australia: Drug and Alcohol Services

    Not in our library

  62. 62.

    Slater E Book Review of "Amphetamine Psychosis" by P. H. ConnellBr Med J1959 21488

    Not in our library

  63. 63.

    Yeh HS Lee YC Sun HJ Wan SR Six months follow-up of patients with methamphetamine psychosisZhonghua Yi Xue Za Zhi (Taipei)2001 647388394

    Not in our library

  64. 64.

    Grelotti DJ Kanayama G Pope HG Jr Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literatureAm J Psychiatry2010 16711723

    Not in our library10.1176/appi.ajp.2009.08111695

  65. 65.

    Yui K Ishiguro T Goto K Ikemoto S Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosisAnn N Y Acad Sci2000 914292302

    Not in our library10.1111/j.1749-6632.2000.tb05204.x

  66. 66.

    Akiyama K Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinenceAnn N Y Acad Sci2006 1074125134

    Not in our library10.1196/annals.1369.012

  67. 67.

    Kittirattanapaiboon P Mahatnirunkul S Booncharoen H Thummawomg P Dumrongchai U Chutha W Long-term outcomes in methamphetamine psychosis patients after first hospitalisationDrug Alcohol Rev2010 294456461

    Not in our library10.1111/j.1465-3362.2010.00196.x

  68. 68.

    Yui K Ikemoto S Goto K Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosisAnn N Y Acad Sci2002 965292304

    Not in our library10.1111/j.1749-6632.2002.tb04171.x

  69. 69.

    Yui K Ikemoto S Goto K Nishijima K Kato S Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosisJ Clin Psychopharmacol2003 235525528

    Not in our library10.1097/01.jcp.0000088919.02635.d7

  70. 70.

    Yui K Goto K Ikemoto S The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrenceAnn N Y Acad Sci2004 1025296306

    Not in our library10.1196/annals.1316.037

  71. 71.

    Robinson TE Becker JB Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosisBrain Res1986 3962157198

    Not in our library10.1016/0165-0173(86)90002-0

  72. 72.

    Strakowski SM Sax KW Rosenberg HL DelBello MP Adler CM Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and toleranceNeuropsychopharmacology2001 254548554

    Not in our library10.1016/s0893-133x(01)00253-6

  73. 73.

    Bartlett E Hallin A Chapman B Angrist B Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability?Neuropsychopharmacology1997 1617782

    Not in our library10.1016/s0893-133x(96)00164-9

  74. 74.

    Chen CK Lin SK Sham PC Ball D Loh EW Hsiao CC Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosisPsychol Med2003 33814071414

    Not in our library10.1017/s0033291703008353

  75. 75.

    Vincent N Schoobridge J Ask A Allsop S Ali R Physical and mental health problems in amphetamine users from metropolitan Adelaide, AustraliaDrug Alcohol Rev1998 172187195

    Not in our library10.1080/09595239800186991

  76. 76.

    Sato M Long-lasting hypersensitivity to methamphetamine following amygdaloid kindling in cats: the relationship between limbic epilepsy and the psychotic stateBiol Psychiatry1983 185525536

    Not in our library

  77. 77.

    Sato M Chen CC Akiyama K Otsuki S Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosisBiol Psychiatry1983 184429440

    Not in our library

  78. 78.

    Myers CS Halladay AK Widmer DA Wagner GC Neurotoxic effects of amphetamine plus L-DOPAProg Neuropsychopharmacol Biol Psychiatry1999 234731740

    Not in our library10.1016/s0278-5846(99)00031-7

  79. 79.

    Iyo M Sekine Y Mori N Neuromechanism of developing methamphetamine psychosis: a neuroimaging studyAnn N Y Acad Sci2004 1025288295

    Not in our library10.1196/annals.1316.036

  80. 80.

    Grace AA Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stressNeurotox Res2010 183–4367376

    Not in our library10.1007/s12640-010-9154-6

  81. 81.
    Increased baseline occupancy of D2 receptors by dopamine in schizophrenia · 2000
    Not checked
  82. 82.

    Seeman P All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2 ReceptorsCNS Neurosci Ther2010 17217551759

    Not in our library10.1111/j.1755-5949.2010.00162.x

  83. 83.

    Lieberman JA Kane JM Alvir J Provocative tests with psychostimulant drugs in schizophreniaPsychopharmacology (Berl)1987 914415433

    Not in our library10.1007/bf00216006

  84. 84.

    Tsuang MT Simpson JC Kronfol Z Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family historyArch Gen Psychiatry1982 392141147

    Not in our library10.1001/archpsyc.1982.04290020013003

  85. 85.

    Chen CK Lin SK Sham PC Ball D Loh E Murray RM Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosisAm J Med Genet B Neuropsychiatr Genet2005 136B18791

    Not in our library10.1002/ajmg.b.30187

  86. 86.

    McKetin R Hickey K Devlin K Lawrence K The risk of psychotic symptoms associated with recreational methamphetamine useDrug Alcohol Rev2010 294358363

    Not in our library10.1111/j.1465-3362.2009.00160.x

  87. 87.

    Salo R Leamon MH Natsuaki Y Moore C Waters C Nordahl TE Findings of preserved implicit attention in methamphetamine dependent subjectsProg Neuropsychopharmacol Biol Psychiatry2008 321217223

    Not in our library10.1016/j.pnpbp.2007.08.012

  88. 88.

    Yui K Ishiguro T Goto K Ikemoto S Precipitating factors in spontaneous recurrence of methamphetamine psychosisPsychopharmacology (Berl)1997 1343303308

    Not in our library10.1007/s002130050453

  89. 89.

    Espelin DE Done AK Amphetamine poisoning. Effectiveness of chlorpromazineN Engl J Med1968 2782513611365

    Not in our library10.1056/nejm196806202782502

  90. 90.

    Leucht S Pitschel-Walz G Abraham D Kissling W Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsSchizophr Res1999 3515168

    Not in our library10.1016/s0920-9964(98)00105-4

  91. 91.

    Shoptaw SJ Kao U Ling W Treatment for amphetamine psychosisCochrane Database Syst Rev2009 1CD003026

    Not in our library10.1002/14651858.cd003026.pub3

  92. 92.

    Leelahanaj T Kongsakon R Netrakom P A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosisJ Med Assoc Thai2005 88Suppl 3S43S52

    Not in our library

  93. 93.

    Drake RE Xie H McHugo GJ Green AI The effects of clozapine on alcohol and drug use disorders among patients with schizophreniaSchizophr Bull2000 262441449

    Not in our library10.1093/oxfordjournals.schbul.a033464

  94. 94.

    Noordsy DL O'Keefe C Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center settingJ Clin Psychiatry1999 60Suppl 194751

    Not in our library

  95. 95.

    Noordsy DL O'Keefe C Mueser KT Xie H Six-month outcomes for patients who switched to olanzapine treatmentPsychiatr Serv2001 524501507

    Not in our library10.1176/appi.ps.52.4.501

  96. 96.

    Foster S Kessel J Berman ME Simpson GM Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room settingInt Clin Psychopharmacol1997 123175179

    Not in our library10.1097/00004850-199705000-00009

  97. 97.

    Allen MH Currier GW Carpenter D Ross RW Docherty JP The expert consensus guideline series. Treatment of behavioral emergencies 2005J Psychiatr Pract2005 111 Suppl5108

    Not in our library10.1097/00131746-200511001-00002

  98. 98.

    Granado N Ares-Santos S Oliva I O'Shea E Martin ED Colado MI Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMANeurobiol Dis2011 423391403

    Not in our library10.1016/j.nbd.2011.01.033

  99. 99.

    Hall HV McPherson SB Yudko E Methamphetamine use - Clinical and forensic aspects2009 Second EditionNew York: CRC Press

    Not in our library

  100. 100.

    Caton CL Drake RE Hasin DS Dominguez B Shrout PE Samet S Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosesArch Gen Psychiatry2005 622137145

    Not in our library10.1001/archpsyc.62.2.137

  101. 101.

    Mathias S Lubman DI Hides L Substance-induced psychosis: a diagnostic conundrumJ Clin Psychiatry2008 693358367

    Not in our library10.4088/jcp.v69n0304

  102. 102.

    Moore TH Zammit S Lingford-Hughes A Barnes TR Jones PB Burke M Cannabis use and risk of psychotic or affective mental health outcomes: a systematic reviewLancet2007 3709584319328

    Not in our library10.1016/s0140-6736(07)61162-3

  103. 103.

    Zammit S Allebeck P Andreasson S Lundberg I Lewis G Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort studyBMJ2002 32573741199

    Not in our library10.1136/bmj.325.7374.1199

  104. 104.

    D'Souza DC Sewell RA Ranganathan M Cannabis and psychosis/schizophrenia: human studiesEur Arch Psychiatry Clin Neurosci2009 2597413431

    Not in our library10.1007/s00406-009-0024-2

  105. 105.

    Degenhardt L Hall W Lynskey M Testing hypotheses about the relationship between cannabis use and psychosisDrug Alcohol Depend2003 7113748

    Not in our library10.1016/s0376-8716(03)00064-4

  106. 106.

    D'Souza DC Cannabinoids and psychosisInt Rev Neurobiol2007 78289326

    Not in our library10.1016/s0074-7742(06)78010-2

  107. 107.

    Callaghan RC Cunningham JK Allebeck P Arenovich T Sajeev G Remington G Methamphetamine use and schizophrenia: a population-based cohort study in CaliforniaAm J Psychiatry2012 1694389396

    Not in our library10.1176/appi.ajp.2011.10070937

  108. 108.

    Hermens DF Lubman DI Ward PB Naismith SL Hickie IB Amphetamine psychosis: a model for studying the onset and course of psychosisMed J Aust2009 1904 SupplS22S25

    Not in our library10.5694/j.1326-5377.2009.tb02370.x

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.